*Yuko Sekino1 (1. Graduate School of Agricultural and Life Sciences,The University of Tokyo / Institute for Drug Discovery Innovation)
Session information
Luncheon Seminarminar
[1LS02] Challenges in Drug Discovery Research Using High-Speed iPS Induced Differentiation Technology (Quick-Tissue™ Technology)
Tue. Aug 1, 2023 11:55 AM - 12:45 PM Room 2 (Tachibana)
Chairperson: Hosoya Toshihiko (RICOH Company, Ltd.)
Sponsored by RICOH Company, Ltd.
The creation of human iPS cells is expected to realize previously difficult drug discovery technologies and pathological analysis. In this seminar, two speakers will talk about recent topics on iPS cell-derived neurons under the title of "Challenges in Drug Discovery Research Using High-Speed iPS Induced Differentiation Technology (Quick-Tissue™ Technology)". The first speaker is Dr. Sekino. The numerous spine structures on the dendrites of pyramidal neurons in the mature brain are microstructures discovered by Ramon y Cajal. Their shape is known to vary depending on the state of the internal actin cytoskeleton. Drebrin, a protein whose expression changes with brain development, is an actin-binding protein that localizes to dendritic spines. We will discuss the memory mechanism from the viewpoint of the dynamic regulation of the actin cytoskeleton by drebrin. The next lecture will be given by Dr. Aiba. Disease-specific iPSC lines are expected to overcome the difficulty of obtaining conventional patient-derived materials and contribute to the advancement of neurological disease and drug discovery research. However, there are challenges in the current situation where many researchers are not fully benefiting from these advantages. The main reasons for this include the immaturity of neurons derived from iPSCs and the difficulty in readily utilizing multiple patient-derived iPSC lines. Our Quick tissue™ technology can solve these problems. In this luncheon seminar, I will provide an overview of the Quick tissue™ technology and the characteristics of the neurons generated by this technique.
*Kazuhiro Aiba1 (1. Elixirgen Scientific, Inc.)